-

Data Economic Derivative Products: A discussion on opportunities to securitize Data Assets

-
 
 
 

With more companies generating data and finding ways to monetize it, alongside rapid growth in digital asset markets, what opportunities exist to create data-backed securities and financial derivative products backed by real world digital data? This session explores the potential for Data Economic Derivative Products, including an overview of the types of instruments that might be developed, what would make them unique compared to other digital asset type instruments such as cryptocurrencies or NFTs, the key features that would distinguish them in the market, and how they might be used to create impact by capturing new avenues for investment or aligning financial incentives in challenging areas.

Session Host

Sirtaj Singh Brar, Director, The Data Economics Company

Sirtaj Singh Brar is a multidisciplinary talent with 15 years of experience, spanning the public sector, pharmaceutical, and financial industries, in helping enterprises solve real world problems through the use of technology solutions. This includes ensuring new software and technologies integrate well across business processes, functions, and the existing technology landscape.

In his current role as Director at DECO, Sirtaj leads product development for Lydion Solutions Platforms built on the Lydion Data Economic Operating System (DEOS), managing projects as they are incubated, developed, and deployed across verticals. He also focuses on continually contributing to the science of Data Economics through new research and application development.

Sirtaj has degrees in Physics and Mathematics from the University of California, Berkeley.

Session Participants

Jason Dispenza, CEO and Co-Founder, EnLedger and Chairman, Building Change


Arka Ray, Managing Director, The Data Economics Company

Technology executive and computer scientist, currently leading the development of the Lydion DEOS (Data Economic Operating System) and overall strategy for the creation and propagation of Lydion Solution Platforms built on Lydion DEOS. Previously built the Sidelines and Popularium content publishing platforms, as well as helped design and launch several games and products on the Xbox Live network as a part of the Xbox and Windows Gaming teams at Microsoft.


Nathan Yates, M.S., Founder of ForwardView Consulting

Nathan earned a Bachelor’s degree in Economics and Finance from Southern New Hampshire University, graduating summa cum laude. He then earned a Master’s degree in Finance from Southern New Hampshire University. Nathan also holds the CFA Institute Investment Foundations and CAIA Association Fundamentals of Alternative Investments credentials.


Vipin Tyagi, PhD, CEO & Co-founder, VerdeEn Chemicals

Vipin is the CEO and Co-founder of VerdeEn Chemicals, a clean-technology company in the battery recycling space. He is passionate about environment, sustainability and entrepreneurship. He co-founded VerdeEn with a mission to innovate and develop zero-emissions battery recycling solutions. Prior to starting VerdeEn, he worked at Bank of America Merrill Lynch in commodity trading and structuring space in Houston and Singapore, where he developed a keen understanding of the commodity markets and value-chains, especially metals and energy.

Vipin holds a Ph.D. in Mechanical Engineering from Texas A&M University and a B. Tech. in Mechanical Engineering from IIT Bombay. During his doctoral dissertation, he developed a novel traffic flow model, which is currently utilized as one of the inputs in predicting trip travel times on Texas freeway network. He has also co-authored several peer reviewed journal and conference publications in the mathematical modeling and controls space.


Viren Mahurkar, CAIA

Specialized in public and private company acquisitions, BD&L, partnerships, collaborations and investments in the pharma, biotech and medtech space. Leverage vast global relationship network of corporates, founders and investors to structure and negotiate high-impact deal opportunities ranging from preclinical, early and late clinical through commercial.

Expertise in leading transactions for Big Pharma, Big MedTech as well as European and Asian family businesses. M&A and BD&L assignments with US, European and Asian pharma, biotechs and medtechs pursuing cutting-edge science. Backed by strong cross-functional operational insights through serving on global and regional leadership teams.